Clinical Guidelines for Type 2 Diabetes Mellitus Management

First-Line Management

• The American College of Physicians strongly recommends adding an SGLT-2 inhibitor or a GLP-1 agonist to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control to reduce mortality and morbidity 1, 2, 3
• Metformin, unless contraindicated, combined with lifestyle modifications remains the cornerstone of initial type 2 diabetes management for most patients 1, 2
• Target HbA1c levels should be between 7% and 8% for most adults, with deintensification of pharmacologic treatments when HbA1c is less than 6.5% 2, 3

Medication Selection Algorithm

• Add second-line therapy when glycemic targets are not met with metformin and lifestyle modifications 1, 2, 3
• For patients with inadequate glycemic control, choose between SGLT-2 inhibitor or GLP-1 receptor agonist, prioritizing based on patient conditions such as heart failure, chronic kidney disease, or increased stroke risk 2, 3
• SGLT-2 inhibitors reduce hospitalization due to congestive heart failure 1, 2, 3
• GLP-1 receptor agonists reduce stroke 1, 2, 3
• DPP-4 inhibitors are NOT recommended as add-on therapy to metformin due to lack of mortality benefit 1, 2, 3

Special Clinical Considerations

• Self-monitoring of blood glucose might be unnecessary in patients receiving metformin combined with either an SGLT-2 inhibitor or a GLP-1 agonist 2, 3
• When adding an SGLT-2 inhibitor or GLP-1 agonist results in adequate glycemic control, reduce or discontinue existing treatment with sulfonylureas or long-acting insulins to avoid hypoglycemia 2, 3
• Sulfonylureas and long-acting insulins are inferior to SGLT-2 inhibitors and GLP-1 agonists in reducing mortality and morbidity but may still have limited value for glycemic control 2, 3
• Consider cost implications when selecting medications, as there are currently no generic SGLT-2 inhibitors or GLP-1 agonists available 3

Collaborative Care Approach

• Implement collaborative care plans that integrate management of comorbidities and concomitant medications 2, 3
• Involve clinical pharmacists to reduce polypharmacy risks 3
• Assess and address social risk factors that may impact diabetes management 3

Common Pitfalls to Avoid

• Overlooking the need to reduce or discontinue sulfonylureas or insulin when adding SGLT-2 inhibitors or GLP-1 agonists, which can lead to hypoglycemia 2, 3